Randomized clinical trials demonstrated impressive activity of ibrutinib and novel BTK inhibitors for the treatment of R/R disease [59,60,61], del(17p) CLL patients [62], and de novo or R/R MCL patients [63,64]. The gene discussed is BTK; the disease is mantle cell lymphoma.